The novel herbal cocktail MA128 suppresses tumor growth and the metastatic potential of highly malignant tumor cells

AEYUNG KIM, MINJU IM, NAM-HIU YIM, YOUN-HWAN HWANG, HYE JIN YANG and JIN YEUL MA

Korean Medicine (KM)-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine (KIOM), Daejeon 305-811, Republic of Korea

Received March 17, 2015; Accepted April 29, 2015

DOI: 10.3892/or.2015.4018

Abstract. MA128, a novel herbal medicine, was previously identified and its effectiveness in the treatment of asthma and atopic dermatitis (AD) was demonstrated. In particular, post-inflammatory hyperpigmentation (PIH) in AD mice was improved by treatment with MA128. In addition, MA128 exhibited anti-melanogenic activity by inhibiting tyrosinase activity via the p38 MAPK and protein kinase A signaling pathways in B16F10 cells. In the present study, we examined whether oral administration of MA128 suppressed the in vivo tumor growth of HT1080 cells in athymic nude mice. The results showed that the daily oral administration of 75 and 150 mg/kg MA128 suppressed the tumorigenic growth of HT1080 cells efficiently. Since metastasis is a major cause of cancer-associated mortality and the greatest challenge during cancer treatment, we investigated the effect of non-toxic concentrations of MA128 on the metastatic potential of HT1080 cells. MA128 inhibited anchorage-independent colony formation, migration and invasion. Matrix metalloproteinase-9 (MMP-9) activity under resting and PMA-stimulated conditions was decreased in a dose-dependent manner by MA128 in HT1080 cells. In addition, the daily oral administration of MA128 at doses of 75 and 150 mg/kg efficiently blocked the lung metastasis of B16F10 cells that had been injected into the tail veins of C57BL/6 mice. In particular, none of the mice treated with MA128 exhibited systemic toxicity, such as body weight loss or liver and kidney dysfunction. MA128 also inhibited tumor-induced angiogenesis. Taken together, the results suggest that MA128 is a potential therapeutic agent and a safe herbal medicine for controlling malignant and metastatic cancer.

Introduction
Malignant tumors consist of cancer cells that usually grow rapidly and spread to other parts of the body via the bloodstream or lymph system by degrading the surrounding tissues and subsequently adapting to form secondary foci known as metastases (1). During the malignant progression, the acquisition of genetic and/or epigenetic alterations causes uncontrolled cell proliferation and resistance to chemotherapy and radiotherapy. In addition, metastatic conversion is one of the main reasons for high mortality rates and a leading cause of the poor clinical outcome of cancer patients, because of its systemic nature and the resistance of disseminated cells to existing therapeutic agents (2). The process of metastasis involves several interdependent processes, including a loss of cell adhesion to the extracellular matrix (ECM), the proteolytic breakdown of tissue barriers, intravasation into the lumina of blood vessels, survival in the circulation, extravasation and the subsequent invasion into new tissues, and metastatic colonization. Therefore, controlling the metastasis and proliferation of already-established tumors is an important therapeutic strategy for the management of malignant tumors (3,4).

Chemotherapy is commonly used to treat cancer. However, current chemotherapy modalities using cytotoxic anti-cancer drugs also destroy normal cells and provide little survival benefit. These modalities also have significant side effects, dose-limiting toxicities and low bioavailability. In many studies, natural herbal medicines control various human diseases, including cancer (5-7). Chinese/Oriental herbal medicines in the form of herbal cocktails have been used to treat a wide range of human diseases and improve the physical strength of patients. Herbal cocktails containing a number of phytochemicals in a single formula have the merit of functioning synergistically by affecting multiple biological and pathological processes, leading to maximal therapeutic effects with minimal side effects (8,9).

Recently, we formulated a novel herbal cocktail termed MA, which is composed of herbal plants that have been used traditionally to control allergic disease and inflammation, including Glycyrrhizae radix, Polygoni cuspidati radix, Sophorae radix, Cnidii rhizoma and Arctii fructus (10,11). To improve the therapeutic efficacy by increasing the absorption and bioavailability of the active components, we fermented MA...
using *Lactobacillus rhamnosus* (*L. rhamnosus*) and designated the product of MA128. MA and MA128 are effective for the treatment of asthma by modulating ovalbumin (OVA)-specific cytokines and atopic dermatitis (AD) by reducing IgE production (10,11). In addition, MA128 had significantly increased efficacy against asthma and AD compared with MA. Recently, MA128 was demonstrated to have anti-melanogenic effects by inhibiting tyrosinase activity (12).

In the present study, we examined the anti-cancer effects of MA128 in terms of the induction of cell death and suppression of metastatic potential in highly malignant tumor cells. We also assessed whether the administration of MA128 was useful for the management of malignant tumor cells in mice without exerting adverse effects.

**Materials and methods**

**Cells and animals.** Human fibrosarcoma HT1080 (KCLB no. 10121) and murine melanoma B16F10 (KCLB no. 80008) cells were purchased from the Korean Cell Line Bank (Seoul, Korea) and maintained in RPMI-1640 or Dulbecco's modified Eagle's medium (DMEM; CellGro, Manassas, VA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; CellGro), 100 U/ml penicillin and 100 µg/ml streptomycin (CellGro) at 37°C in a humidified incubator with 5% CO₂.

Human umbilical vein endothelial cells (HUVECs) were purchased from InnopharmaScreen (Asan, Korea) at passage 2, maintained in endothelial cell growth medium-2 (EGM-2; PromoCell, Heidelberg, Germany), and used for experiments at passages 3-9. For the animal experiments, female athymic nude mice were purchased from Nara Biotech (Seoul, Korea). Female C57BL/6 mice and male Sprague Dawley rats were obtained from Taconic Farms Inc. (Samtako Bio Korea, Osan, Korea).

All animals were housed under controlled conditions using a 12/12-h light/dark cycle at 22±1°C and 55±5% humidity under specific pathogen-free conditions. All animal experiments were approved by the Animal Care and use Committee at KIOM. The authenticity of the plant species was validated by Professor Ki Hwan Bae (Chungnam national university, Daejeon, Korea), with the reference numbers #13-42, #13-48 and #14-27, respectively. Antibodies against p21, p27, cyclin B, cyclin D, p38, p-p38 (Thr180/Tyr182), ERK1/2, p-ERK1/2 (Thr202/Tyr204), JNK, p-JNK (Thr183/Tyr185), Akt, p-Akt (Ser473), mTOR, p-mTOR (Ser2481), IκΒα, p-IκΒα (Ser32/36), p-4e-BP1 (Thr37/46), MMP-9 and tubulin were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-HIF-1α antibodies were obtained from BD Biosciences.

**Preparation of the fermented herbal cocktail MA128.** Herbs used for the preparation of MA128, including *Glycyrrhiza radix*, *Polygoni cuspidati radix*, *Sophora radix*, *Cnidii rhizoma*, and *Arctii fructus*, were purchased from Yeongcheon Oriental Herbal Market (Yeongcheon, Korea), and all voucher specimens were deposited in the herbal bank in KIOM. The authenticity of the plant species was validated by Professor Ki Hwan Bae (Chungnam National University, Daejeon, Korea). Pure *L. rhamnosus* KFR1128 cultures were obtained from the Korea Food Research Institute (KFRI) and incubated in MRS medium for 24 h at 37°C as described previously (12). A total of 1,840 g MA was soaked in 18.4 l distilled water (DW) and then heat-extracted for 3 h at 115°C using an extractor (Cosmos-600 Extractor; Gyeoneseo Co., Incheon, Korea). After filtration through standard testing sieves (150 µm; Retsch, Haan, Germany), the pH of decoction MA was adjusted to 8.0 using 1 M NaOH. It was then sterilized at 5 min at 121°C using an autoclave. For the fermentation of decoction MA, 10 ml *L. rhamnosus* (1x10⁶ CFU/ml) was added to 10 liter decoction MA and incubated at 37°C for 48 h. The fermented MA, designated as MA128, was filtered through a 60-µm nylon net filter (Millipore, Bedford, MA, USA), freeze-dried and stored in a desiccator at 4°C. A total of 376 g MA128 powder was produced and the yield was 20.44%. The freeze-dried MA128 powder was dissolved in 10% (v/v) DMSO in DW and centrifuged at 14,000 rpm for 10 min. The supernatant was filtered (0.2-µm, pore size) and kept at 4°C prior to use.

**Reagents and antibodies.** Type A gelatin from porcine skin, fibronectin from human plasma, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), phorbol 12-myristate 13-acetate (PMA) and mitomycin C were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Type I collagen solution (0.3%, Cellmatrix type I-A) and the growth factor-reduced Matrigel basement membrane matrix were purchased from Nitta Zerachin, Inc. (Osaka, Japan) and BD Biosciences (Bedford, MA, USA), respectively. Antibodies against p21, p27, cyclin B, cyclin D, p38, p-p38 (Thr180/Tyr182), ERK1/2, p-ERK1/2 (Thr202/Tyr204), JNK, p-JNK (Thr183/Tyr185), Akt, p-Akt (Ser473), mTOR, p-mTOR (Ser2481), IκΒα, p-IκΒα (Ser32/36), p-4e-BP1 (Thr37/46), MMP-9 and tubulin were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-HIF-1α antibodies were obtained from BD Biosciences.

**Chemicals.** For high-performance liquid chromatography (HPLC), HPLC-grade acetonitrile and trifluoroacetic acid (TFA) were purchased from J.T. Baker (Phillipsburg, NJ, USA) and Sigma, respectively. Icarin and glycyrrhizin were obtained from the Tokyo Chemical Industry Co. (Tokyo, Japan). Matrine, chlorogenic acid, nodakenin and arctin were purchased from Faces Biochemical Co. (Wuhan, China). Arctigenin and decursin were obtained from Tocris Biosciences (Bristol, UK) and KFDA (Osong, Korea), respectively.

**In vivo assays used to assess the effect of MA128 on tumor growth and pulmonary metastasis.** Five-week-old female athymic nude mice were inoculated subcutaneously with 2x10⁶ HT1080 cells/mouse in the femoral region. On day 5, the mice were divided randomly into 3 groups (n=5 per group) and treated daily with saline (control) or MA128 (75 or 150 mg/kg) in a volume of 100 µl for 12 days. Tumor volume and weight were measured as previously described (13). To induce pulmonary metastasis, C57BL/6 mice were injected intravenously with B16F10 cells (3x10⁵ cells/mouse) via the tail vein. After being divided randomly into 3 groups (n=4 per group), the mice were administered saline (control) or MA128 at 75 or 150 mg/kg. After daily treatment for 17 days, the mice were sacrificed, their lungs were fixed in Bouin's solution (Sigma), and metastasized black colonies were counted macroscopically. To assess the safety of MA128, 5-week-old athymic nude mice and C57BL/6 mice (n=3 for each group) were treated daily with vehicle (saline) or MA128 (75 or 150 mg/kg) for 14 and 15 days, respectively. Body weight was measured daily, and the weights of the major organs, including the liver, heart, lung, spleen and kidneys, were measured at the time of sacrifice. Serological and hematological parameters were analyzed using XL 200 (Erba Diagnostics, Mannheim, Germany) and
an ADVIA 2120i hematology system (Siemens Healthcare Diagnostics, Tarrytown, NY, USA), respectively.

**Cell viability assay.** To examine the effects of MA128 on cell proliferation, 5x10³ cells/well in a 96-well plate were treated with various concentrations of MA128 (50-1,000 µg/ml) for 48 h, and MTT assays were then performed as previously described (13).

**Colony formation assay.** To assess anchorage-independent cell growth, 5x10³ cells were suspended in 2 ml medium containing the indicated concentrations of MA128, 10% FBS, and 0.3% agar, and then applied over the bottom agar that had been pre-solidified with 3 ml medium containing 10% FBS and 0.6% agar. During incubation, colony formation was observed daily under a phase-contrast microscope, and images were captured.

**Adhesion assays on immobilized FN and type I collagen.** Cell-to-ECM adhesion was measured in 96-well culture plates as reported previously with slight modifications (14). After coating the plates with 50 µl FN (5 µg/ml) or 0.3% type I collagen solution overnight at room temperature, the wells were washed with cold PBS, blocked with medium containing 0.3% BSA (200 µl/well) and then washed again. MA128 pre-treated cells were suspended in serum-free medium at a density of 5x10³/ml, plated on FN- or type I collagen-coated wells (200 µl/well), and then allowed to adhere for 1 h at 37˚C. Unattached cells were removed by washing and the attached cells were stained using 0.2% crystal violet/20% methanol (w/v) solution. After staining, the cells were dissolved in 1% SDS solution, and the spectrophotometric absorbance was measured at 560 nm.

**Wound-healing cell migration assay.** The cells were pre-incubated with mitomycin C (25 µg/ml) for 30 min to inhibit proliferation. Subsequently, they were injured by scraping across the cell monolayer. After washing to remove floating cell debris, the cells were allowed to migrate in the presence of MA128 and monitored under a phase-contrast microscope.

**Transwell migration/invasion assays.** Migration/invasion assays were performed using Transwell chambers with polyethylene tetrathalate membranes (6.5-mm diameter and 8-µm pore size) as described previously with slight modifications (14,15). For the invasion assays, the membranes were coated with 50 µl Matrigel (diluted in RPMI-1640, 1:8) to form an intervening invasive barrier.

**Gelatin zymography.** Cells plated in 12-well culture plates at 80% confluence were pre-incubated with MA128 in serum-free media for 12 h and then stimulated with 5 nM PMA for an additional 24 h. Conditioned media (CM) were collected and electrophoresed using 8% SDS-PAGE containing 0.1% gelatin. After washing, the gels were incubated for 24 h and then stained and de-stained as previously described (14,15). MMP-9 was detected as a clear 92-kDa band against the blue background.

**Tube formation assay.** Capillary-like tube formation was assayed using HUVECs, an ECMatrix assay kit (Millipore, Temecula, CA, USA), and µ-Slide Angiogenesis ibiTreat chambers (ibidi GmbH, Germany), as previously described (16). HUVECs (5x10³ cells) were suspended in 50 µl MA128-treated HT1080 CM, seeded onto the surface of polymerized ECMatrix, and incubated for 4-8 h at 37˚C in an incubator containing 5% CO₂. The cellular tube networks were observed using a phase-contrast microscope and photographed, and the relative tube area was quantified in five fields of view per well.

**Rat aortic ring assay.** Dorsal aortas isolated from Sprague Dawley rats were cut transversely into 1-mm thick rings. Each aortic ring was then placed in 48-well culture plates pre-coated with 100 µl Matrigel. After sealing the rings with 40 µl Matrigel, 400 µl EGM-2 was added to the wells and the plates were incubated for 3 days to allow microvessel sprouting from the aortic rings. The EGM-2 was then replaced with control or MA128-treated CM, and microvessel outgrowths were observed and photographed for an additional day.

**Western blotting.** Whole cell lysates were extracted using M-PER Mammalian Protein Extraction reagent (Thermo Scientific, Rockford, IL, USA). Equal amounts of protein were resolved using 8-15% SDS-PAGE, incubated with specific antibodies, and detected as previously described (13). The band intensities were analyzed using ImageJ software.

**Determining VEGF, PDGF and bFGF levels using ELISA.** The cells were incubated with the indicated concentrations of MA128 for 48 h. The levels of VEGF, PDGF, and bFGF in control and MA128-treated CM were determined using a Human ELISA Development kit (Peprotech, Rocky Hill, NJ, USA) according to the manufacturer's instructions.

**Chromatographic analysis of MA128.** The phytochemical profile of MA128 was measured using HPLC analysis on HPLC-DAD (LaChrom Elite, Hitachi High-Technologies Co., Tokyo, Japan), and chromatographic separation was achieved on a Phenomenex Luna C18 column (4.6x250 mm, 5 µm). A gradient elution of 10% acetonitrile in deionized water containing 0.05% TFA (A) and 60% acetonitrile in deionized water containing 0.05% TFA (B) was performed as follows: 0-25 min with 0% B; 25-100 min with 0-45% B; 100-110 min with 15-100% B; 110-120 min with 100% B; 120-122 min with 100-0% B; and 122-140 min with 0% B. The flow rate and injection volume were 1 ml/min and 10 µl, respectively. HPLC chromatograms were obtained using UV at 190-400 nm. Standard (ST), ST-spiked sample (SP), and sample solutions were dissolved and diluted in methanol.

**Statistical analysis.** Data are presented as mean ± standard deviation (SDs). The statistical significance of the differences between groups was analyzed using a two-way analysis of variance (ANOVA) and the Student's t-test with SigmaPlot 8.0 software. P<0.05 was considered to indicate significant differences.

**Results**

MA128 inhibits the in vivo tumorigenic growth of HT1080 cells with no adverse effects. Prior to determining the anti-cancer effects of MA128 in athymic nude mice, we assessed whether the repeated administration of 75 or 150 mg/kg
MA128 elicited systemic toxicity. The MA128 doses used were according to the amounts administered to human adults (36.8 g/day/60 kg of body weight) and the yield of the extrac- tion. Fourteen days of MA128 administration did not cause death or abnormal behavior. Body and organ weights, the ratios of GOT/GPT and BUN/CRe, and the hematological parameters were also measured. RBC, red blood cell count; Hb, hemoglobin; PLT, platelet; neutrophil; LYM, lymphocyte; MONO, monocyte. Data are presented as mean ± SD.

**Table I. Safety measurement in athymic nude mice after oral administration of 75 or 150 mg/kg MA128.**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>75 mg/kg</th>
<th>150 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>24.66±0.46</td>
<td>23.98±1.59</td>
<td>24.52±0.48</td>
</tr>
<tr>
<td>Day 14</td>
<td>25.05±0.48</td>
<td>24.54±1.31</td>
<td>25.23±0.54</td>
</tr>
<tr>
<td>Organ weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>1.15±0.04</td>
<td>1.11±0.11</td>
<td>1.14±0.04</td>
</tr>
<tr>
<td>Heart</td>
<td>0.12±0.01</td>
<td>0.11±0.01</td>
<td>0.12±0.01</td>
</tr>
<tr>
<td>Lung</td>
<td>0.17±0.01</td>
<td>0.18±0.01</td>
<td>0.18±0.02</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.11±0.02</td>
<td>0.12±0.02</td>
<td>0.12±0.01</td>
</tr>
<tr>
<td>Kidney (L)</td>
<td>0.15±0.01</td>
<td>0.12±0.01</td>
<td>0.14±0.01</td>
</tr>
<tr>
<td>Kidney (R)</td>
<td>0.14±0.01</td>
<td>0.13±0.01</td>
<td>0.14±0.02</td>
</tr>
<tr>
<td>Chemical analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOT (IU/l)</td>
<td>58.21±5.46</td>
<td>54.67±8.33</td>
<td>53.68±3.61</td>
</tr>
<tr>
<td>GPT (IU/l)</td>
<td>28.67±8.08</td>
<td>31.33±8.08</td>
<td>26.04±8.72</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>22.07±1.36</td>
<td>23.47±1.29</td>
<td>19.34±1.10</td>
</tr>
<tr>
<td>CRE (mg/dl)</td>
<td>0.47±0.01</td>
<td>0.53±0.23</td>
<td>0.48±0.04</td>
</tr>
<tr>
<td>Hematological analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBC (x10^6 cells/µl)</td>
<td>8.85±0.41</td>
<td>8.51±0.49</td>
<td>8.83±0.18</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>13.77±0.51</td>
<td>13.69±0.62</td>
<td>13.95±0.35</td>
</tr>
<tr>
<td>PLT (x10^3/µl)</td>
<td>11.67±0.24</td>
<td>10.71±2.37</td>
<td>11.27±1.11</td>
</tr>
<tr>
<td>NEUT (%)</td>
<td>38.71±2.77</td>
<td>31.87±5.21</td>
<td>33.05±3.89</td>
</tr>
<tr>
<td>LYM (%)</td>
<td>53.51±4.00</td>
<td>60.57±8.11</td>
<td>60.55±4.03</td>
</tr>
<tr>
<td>MONO (%)</td>
<td>1.93±0.75</td>
<td>1.54±0.21</td>
<td>1.43±0.14</td>
</tr>
</tbody>
</table>

Each group of female athymic nude mice (n=3) was administered with 75 or 150 mg/kg MA128 or the same volume of saline daily. After sacrifice, body and organ weights, and the levels of GOT, GPT, BUN, and CRE were analyzed. GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; BUN, blood urea nitrogen; CRE, creatinine. Hematologic parameters were also measured. RBC, red blood cell count; Hb, hemoglobin; PLT, platelet; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte. Data are presented as mean ± SD.

**Table II. Safety measurement in C57BL/6j mice after oral administration of 75 or 150 mg/kg MA128.**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>75 mg/kg</th>
<th>150 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>17.43±0.36</td>
<td>17.26±0.24</td>
<td>17.85±0.35</td>
</tr>
<tr>
<td>Day 15</td>
<td>19.20±0.41</td>
<td>19.93±0.72</td>
<td>20.58±0.87</td>
</tr>
<tr>
<td>Organ weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>1.08±0.04</td>
<td>1.13±0.03</td>
<td>1.05±0.07</td>
</tr>
<tr>
<td>Heart</td>
<td>0.10±0.02</td>
<td>0.11±0.01</td>
<td>0.11±0.01</td>
</tr>
<tr>
<td>Lung</td>
<td>0.15±0.01</td>
<td>0.16±0.02</td>
<td>0.18±0.01</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.08±0.01</td>
<td>0.09±0.01</td>
<td>0.09±0.01</td>
</tr>
<tr>
<td>Kidney (L)</td>
<td>0.12±0.01</td>
<td>0.13±0.01</td>
<td>0.12±0.01</td>
</tr>
<tr>
<td>Kidney (R)</td>
<td>0.12±0.01</td>
<td>0.13±0.01</td>
<td>0.12±0.01</td>
</tr>
<tr>
<td>Chemical analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOT (IU/l)</td>
<td>52.74±3.11</td>
<td>53.37±2.32</td>
<td>54.08±2.04</td>
</tr>
<tr>
<td>GPT (IU/l)</td>
<td>29.31±4.62</td>
<td>27.38±2.47</td>
<td>27.14±1.42</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>36.52±1.54</td>
<td>34.78±1.84</td>
<td>33.49±2.66</td>
</tr>
<tr>
<td>CRE (mg/dl)</td>
<td>0.71±0.16</td>
<td>0.59±0.15</td>
<td>0.57±0.21</td>
</tr>
</tbody>
</table>

Each group of female C57BL/6 mice (n=3) was administered with 75 or 150 mg/kg MA128 or the same volume of saline daily. After sacrifice, body and organ weights, and the levels of GOT, GPT, BUN, and CRE were analyzed. GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; BUN, blood urea nitrogen; CRE, creatinine. Hematologic parameters were also measured. RBC, red blood cell count; Hb, hemoglobin; PLT, platelet; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte. Data are presented as mean ± SD.

MA128 decreases cell viability, increases cell cycle- and cell death-associated protein expression, and activates p38 and ERK in HT1080 cells. MTT assays were used to assess the effect of MA128 on the growth of cells treated with specified concentrations of MA128 for 48 h. As shown in Fig. 2A, cell viability was not altered by 50-250 µg/ml MA128 compared with the untreated control cells, whereas treatment with 500 and 1,000 µg/ml MA128 caused a marked decrease in cell viability and induced most cells to shrink and float (Fig. 2B). Western blotting revealed that MA128 increased the levels of the cyclin-dependent kinase inhibitors p21 and p27 in a dose-dependent manner, whereas it decreased the levels of
cyclin B and D compared with the control cells (Fig. 2C). In addition, MA128 increased the levels of the pro-apoptotic proteins Bad and Bax and decreased the levels of anti-apoptotic Bcl-2 and XIAP (Fig. 2C). It was reported previously that the MAPK signaling pathways can induce cell proliferation or death depending on the stimulus and cell type (17-19). As shown in Fig. 2D, cytotoxic doses of MA128 elevated the levels of phosphorylated p38 and eRK significantly but had little effect on Jnk activation. To confirm the roles of p38 and ERK activation in MA128-mediated cell death, the cells were pre-incubated with or without pharmacological inhibitors of p38 (SB203580), ERK (PD98059), or Jnk (SP600125) for 1 h and then treated with MA128 for 48 h. As shown in Fig. 2E, SB203580 and PD98059 moderately protected MA128-treated cells from death by ~50%, whereas SP600125 had little effect. This result suggested that p38 and ERK activation play roles in MA128-mediated cell death.

**MA128 inhibits the in vivo pulmonary metastasis of B16F10 cells with no adverse effects.** Prior to assessing the anti-metastatic effects of MA128 in C57BL/6 mice, the safety of MA128 treatment was assessed over a 15-day period. As shown in Table II, MA128 did not induce any adverse effects, such as loss of body weight or differences in organ weights. In addition, there were no critical differences in the serological or hematological parameters between MA128-treated and control mice. After confirming safety, we evaluated whether MA128 reduced the pulmonary metastasis of B16F10 cells injected intravenously into the tail vein of C57BL/6 mice. As shown in Fig. 3A and B, B16F10 cells metastasized to the lungs of control mice and formed a considerable number of black colonies (939.81±83.98). However, the incidence of metastatic colonies in mice treated with 75 and 150 mg/kg MA128 was decreased significantly by ~57.9% (395.33±75.72) and 61.1% (365.67±105.19), respectively, compared with the control mice. These results suggested that MA128 intake suppressed the pulmonary metastasis of B16F10 cells efficiently without causing systemic toxicity. To examine the anti-metastatic effects of MA128 *in vitro*, we monitored the cell-to-ECM adhesion, migration, and invasion of B16F10 cells in the presence or absence of MA128. Pre-treatment with MA128 inhibited the attachment of cells to FN and collagen in a dose-dependent manner (Fig. 3C). In the Transwell culture system, serum-induced migration and invasion were markedly...
reduced by MA128 to ~10.6-25.8 and 15.7-41.2% in the control cells, respectively (Fig. 3D).

MA128 suppresses PMA-induced migration and invasion by suppressing MMP-9 activity and blocking NF-κB activation.
in HT1080 cells. To clarify the anti-metastatic mechanism of action of MA128, HT1080 cells and PMA were used under the conditions as previously described (20-22). At the non-toxic concentrations of 50-250 µg/ml, MA128 treatment prevented HT1080 anchorage-independent colony formation (Fig. 4A) and the adhesion to FN and collagen (Fig. 4B) in a dose-dependent manner. Results of the wound-healing assay showed that the control HT1080 cells repaired the wounded area efficiently to ~35 and 70% levels after 18 and 40 h, respectively. By contrast, MA128 treatment inhibited wound repair significantly, allowing only ~10 and 15% healing at 18 and 40 h, respectively (Fig. 4C). In addition, the ability of HT1080 cells to undergo Transwell migration and invasion was markedly increased by PMA stimulation, whereas MA128 almost completely inhibited migration and invasion under PMA-stimulated conditions (Fig. 4D), suggesting that MA128 exerted potent anti-metastatic effects. To elucidate the mechanism by which MA128 inhibited the metastatic potential, we examined whether MA128 suppressed the expression and activity of MMP-9, which is essential for facilitating tumor metastasis by degrading the surrounding ECM.

As shown in Fig. 5A, PMA strongly induced the gelatinolytic activity and secretion of MMP-9, as determined using gelatin zymography and western blotting. By contrast, treatment with MA128 markedly inhibited the PMA-induced increase in MMP-9 activity and expression in a dose-dependent manner.

Figure 3. MA128 markedly inhibits the in vivo pulmonary metastasis and in vitro adhesion, migration, and invasion of B16F10 cells at non-toxic concentrations. (A) Cells (3x10^5/mouse in 200 µl PBS) were injected into the tail vein of C57BL/6 mice, which were then treated daily with 75 and 150 mg/kg MA128 (*n=4 per group). On day 17, the mice were sacrificed, and the F, front and B, back of the lungs were photographed. (B) Black colonies on the lung surface were counted macroscopically, and data are presented as mean ± SD. *P<0.05 vs. control (saline). (C) B16F10 cells pre-incubated with or without MA128 were seeded in FN- or collagen-coated wells, incubated for 1 h, and then washed to remove unattached cells. (D) B16F10 cells pre-incubated with or without MA128 were added into the upper well of Transwell chambers and incubated for 24 h (migration) or 48 h (invasion). (C and D) Cells were stained with 0.2% crystal violet/20% methanol (w/v) solution, and the relative degrees of adhesion, migration, and invasion were calculated. Data are presented as mean ± SD. *P<0.05 vs. untreated control.
manner. Since the transcription factor NF-κB is critical for MMP expression and invasion in various cancer cells (23,24), we examined the effects of MA128 on PMA-induced NF-κB activation. As shown in Fig. 5B, PMA treatment markedly increased the phosphorylation and degradation of IκBα in HT1080 control cells. However, MA128 significantly inhibited PMA-induced IκBα phosphorylation and degradation. Consequently, the p-IκBα/IκBα ratio was much lower in the MA128-treated cells compared with that in the control cells. Taken together, these results suggested that non-toxic doses of MA128 suppress the metastatic potential of HT1080 cells by reducing MMP-9 activity and inhibiting NF-κB activation.

MA128 attenuates tumor-induced angiogenesis by reducing the production of angiogenic factors. Tumor-induced angiogenesis, the formation of new blood vessels from existing
vasculature, is induced by tumor cells and is critical for sustained tumor growth and metastasis (25-27). It has been reported that supernatants harvested from various tumor cells triggered an angiogenic response. Therefore, we examined the ability of HUVECs to form network structures on Matrigel after incubation with control or MA128-treated CM derived from HT1080 cell cultures. As shown in Fig. 6A, control CM stimulated HUVECs to assemble into tube-like structures on Matrigel, whereas MA128-treated CM significantly reduced tube formation in terms of the number, length, and area of capillary-like structures in a dose-dependent manner. Using ex vivo angiogenesis assay, we assessed microvessel sprout formation in rat aortic rings, after incubation with control or MA128-treated CM from HT1080 cells. As reported previously, control CM from HT1080 cells triggered microvessel sprouting around the aortic rings (16), whereas the length of the sprouting microvessels around the aortic rings incubated with MA128-treated CM was markedly shorter than that with control CM (Fig. 6B). As tumor-induced angiogenesis is affected by tumor cell-produced angiogenic factors, the levels of pro-angiogenic factors, including VEGF-α, PDGF and bFGF, were measured in the control and MA128-treated CM from HT1080 cells. As shown in Fig. 6C, ELISA revealed that MA128 treatment significantly reduced the production of angiogenic factors in a dose-dependent manner (Fig. 6C). Angiogenic factors are immediate downstream targets of HIF-1α (28). Therefore, we assessed the effect of MA128 on HIF-1α production. MA128 reduced CoCl₂-stimulated HIF-1α protein accumulation, which was accompanied via inhibition of Akt/mTOR/4 e-BP-1 signaling (Fig. 6D). This result suggested that MA128 decreased tumor-induced angiogenesis by inhibiting the production of angiogenic factors via the suppression of HIF-1α accumulation.

Identifying the main components in MA128 using HPLC. HPLC identified eight phytochemicals in MA128: matrine, chlorogenic acid, nodakenin, arctiin, icariin, arctigenin, and decursin. To achieve the desired separation, a gradient elution of water and acetonitrile was applied. TFA was added to advance the peak shape and inhibit peak tailing, and the UV wavelengths of the eight components were adjusted based on the maximum UV spectra absorption of each component. As shown in Fig. 7, matrine, nodakenin, arctiin, icariin, arctigenin, and decursin were detected at 203 nm, and chlorogenic acid and glycyrrhizin were detected at 254 and 320 nm, respectively. Each component in MA128 was identified by comparing the retention time (tR) and UV spectra with known data. Profiles corresponding to matrine (1, tR 5.3 min), chlorogenic acid (2, tR 11.3 min), nodakenin (3, tR 52.7 min), arctiin (4, tR 76.6 min), icariin (5, tR 89.1 min), arctigenin (6, tR 105.2 min), glycyrrhizin (7, tR 109.6 min), and decursin (8, tR 119.7 min) were identified in MA128.

Discussion

It has been reported that interfering with critical steps of cancer growth and progression, including metastasis and angiogenesis, using naturally occurring herbal agents and phytochemicals is important for reducing the morbidity and mortality of cancer patients (7,29,30). Properly formulated herbal cocktails have the advantage of synergism among individual herbs and improved therapeutic efficacy by targeting various cell pathways while minimizing side effects. Although Chinese/Oriental herbal medicine has long been used to control malignancies, quality control of the active ingredients, safety assessment and elucidation of the mechanism of action must be accompanied by medicinal efficacy for their therapeutic value in modern medicine (31). Rigorous and systematic pre-clinical animal studies that support their efficacy, safety, and underlying mechanisms are essential for transforming traditional herbal practice into ‘evidence-based medicine’.

We developed a novel mixture of medicinal herbs known as MA128, comprising several herbs that have been used traditionally to treat inflammatory and allergic diseases and have been fermented with L. rhamnosus to improve their therapeutic potential. In previous studies, we demonstrated that the oral administration of MA and MA128 ameliorated the major clinical signs of AD including erythema/darkening, edema, excoriations and dryness in AD-induced BALB/c mice. It also exhibited anti-asthmatic effects by suppressing the infiltration of eosinophils into the airway and blood and...
reducing allergic airway inflammation in asthma-induced BALB/c mice. In addition, the therapeutic efficacy of MA128 in these two experimental models was increased significantly by fermentation (11,21).

In the present study, we have demonstrated that MA128 inhibits the proliferation, metastasis, and tumor-induced angiogenesis of malignant tumor cells in vitro and in vivo, with no apparent side effects. This finding suggests that MA128 may be used as a safe and effective remedy for controlling malignant tumor cells. In previous studies, individual herbs in MA128, including Sophorae radix, Polugoni cuspidati radix, Arctii fructus, and Angelica gigantis radix, were shown to elicit anti-cancer effects by inhibiting cell proliferation and inducing apoptosis (32-35). We used HPLC to identify eight phytochemicals in MA128. Of these, previous studies have shown that decursin inhibits the lung metastasis of CT-26 murine colon carcinoma by targeting MMP-9 activity via the suppression of eRK and jnK phosphorylation, inducing cell cycle arrest and apoptosis in human carcinomas, including prostate, colon, and bladder, and by inhibiting VegF-induced angiogenesis, suggesting that it plays a crucial role in mediating anti-cancer activity (36-38). In addition, matrine and glycyrrhizin inhibited cell proliferation and induced apoptosis in many human carcinomas (39-41), whereas matrine reduced

Figure 6. MA128 suppresses tumor-induced angiogenesis. (A) The capillary-like tube formation of HUVECs induced by control or MA128-treated CM isolated from HT1080 cells was examined. The total tube area was measured using ImageJ and shown as the mean ± SD of three random fields. *P<0.05 vs. control CM. (B) Freshly prepared aortic rings were placed in Matrigel-coated 48-well culture plates and incubated with control or MA128-treated CM harvested from HT1080 cells. After 7 days, the microvessels sprouting from rat aortic rings was photographed, and the length of the microvessels was measured. Data are presented as the mean ± SD of three random fields. *P<0.05 vs. control CM. (C) HT1080 cells were treated with or without MA128, and the levels of VEGF-α, PDGF and bFGF in the CM were determined using ELISA. Data are presented as the mean ± SD of assays performed in triplicate. *P<0.05 vs. untreated control. (D) HT1080 cells pre-incubated with or without MA128 were stimulated with 100 µM CoCl₂ for 6 h. The levels of HIF-1α, phosphorylated Akt, mTOR, and 4E-BP-1 were then measured by western blotting, and the relative ratios were calculated after normalization to tubulin using ImageJ.
the invasion of A375 human malignant melanoma cells (42). Icariin exerted negative effects on the invasion and migration of BGC-823 human gastric cancer cells by reducing Rac1 and VASP expression (43). It also induced apoptosis in SMMC-7721 human hepatoma cells by generating ROS via the activation of JNK (44). These results suggest that MA128 has the potential to suppress cell proliferation, migration, invasion, and angiogenesis via these active components.

Tumor-induced angiogenesis is dependent on the release of pro-angiogenic factors, such as VEGF, PDGF, bFGF, angiopoietin and MMPs by tumor cells. These factors in turn stimulate existing blood vessels to initiate angiogenesis. Without angiogenesis, tumor masses are restricted to a few millimeters due to a lack of oxygen and nutrients, and they cannot escape into the circulation to metastasize (25). It has been reported that MMP-2, MMP-9, and VEGF expression levels were positively correlated with tumor size, lymphatic and venous invasion, and lymph node metastasis, as well as malignant progression (45). In the present study, treatment with non-toxic concentrations of MA128 decreased the production of MMP-9 and pro-angiogenic factors in CM significantly by inhibiting NF-κB activation and HIF-1α accumulation. Therefore, the proteolytic activity against gelatin, migration/invasion through Matrigel, and tumor-induced angiogenesis were decreased in MA128-treated cells compared with the control cells. In addition, higher concentrations of MA128 induced cell death efficiently by inducing p38 and eRK phosphorylation. In animal models, the oral administration of 75 and 150 mg/kg MA128 markedly suppressed the growth of HT1080 cells and pulmonary metastasis of B16F10 cells. Safety evaluation of MA128 in athymic nude mice and C57BL/6 mice revealed that the oral administration of 75 and 150 mg/kg MA128 during the experimental period did not cause any systemic toxicity with respect to body weight loss, organ abnormalities, or changes in serological/hematological parameters. This finding suggests that MA128 is a safe and effective cancer treatment. Of note, none of the individual herbs exhibited anti-cancer activities in HT1080 cells at the concentrations present in

![Graph A](image1.png)

UV wavelength: 203 nm

![Graph B](image2.png)

UV wavelength: 254 nm

![Graph C](image3.png)

UV wavelength: 320 nm

Figure 7. Chromatograms of eight major standard compounds (ST), spiked samples (SP), and MA128 identified at UV wavelengths of (A) 203 nm, (B) 254 nm, and (C) 320 nm. Matrine (1), chlorogenic acid (2), nodakenin (3), arctiin (4), icariin (5), arctigenin (6), glycyrrhizin (7) and decursin (8) were identified.
MA128, suggesting that the herbs present in MA128 exerted synergistic and reciprocal effects.

In summary, the current data clearly demonstrate that higher concentrations of MA128 induced cell death, primarily via p38 and ERK activation, and non-toxic concentrations of MA128 suppressed metastatic activity by inhibiting the production of MMP-9 and pro-angiogenic factors in malignant tumor cells. Furthermore, MA128 exhibited potent anti-cancer efficacy against tumor growth and pulmonary metastasis in mice with no adverse effects. These results collectively suggest that MA128 is a safe and efficacious herbal remedy against malignant tumors.

Acknowledgements

This study has been supported by the grant K14050 awarded to the Korea Institute of Oriental Medicine (KIONOM) from the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea.

References